✦ LIBER ✦

Health Canada approves Gleevec for newly diagnosed patients with chronic myeloid leukaemia

Book ID: 120858675
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2003
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200314120-00056

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Techniques for risk stratification of ne

Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia

✍ Mitchell, Birgitta; Deininger, Michael 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 499 KB

Cost-effectiveness of imatinib versus in

Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

✍ Shelby D. Reed; Kevin J. Anstrom; Jennifer A. Ludmer; G. Alastair Glendenning; K 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views

## Abstract ## BACKGROUND Despite a lack of long‐term data, imatinib has become standard therapy for patients with newly diagnosed chronic‐phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the increment

Long-term survival estimates for imatini

Long-term survival estimates for imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

✍ Kevin J. Anstrom; Shelby D. Reed; Andrew S. Allen; G. Alastair Glendenning; Kevi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

KIR2DS1 genotype predicts for complete c

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

✍ Marin, D; Gabriel, I H; Ahmad, S; Foroni, L; Lavallade, H de; Clark, R; O'Brien, 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 349 KB

Cost-Effectiveness Study Comparing Imati

Cost-Effectiveness Study Comparing Imatinib with Interferon-α for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Health-Care System Perspective (CPHSP)

✍ Zi Chen; Chun Wang; Xiaoping Xu; Weiwei Feng 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Nilotinib versus imatinib for the treatm

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

✍ Hagop M Kantarjian; Andreas Hochhaus; Giuseppe Saglio; Carmino De Souza; Ian W F 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 319 KB